Related Experiment Video
Updated: Jun 16, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
Strategies for shortening tuberculosis therapy
Véronique A Dartois1, Valerie Mizrahi2, Radojka M Savic3
1Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Nutley, NJ, USA. veronique.dartois@hmh-cdi.org.
Optimizing tuberculosis (TB) treatment duration requires patient stratification. Innovative strategies using host and pathogen factors can personalize therapy, reducing treatment length and overtreatment for better global TB control.
Area of Science:
- Infectious Diseases
- Microbiology
- Public Health
Background:
- Current tuberculosis (TB) treatment often involves overtreatment due to a lack of patient-stratification methods.
- Shortening TB treatment duration while maintaining efficacy is a major global health priority.
Purpose of the Study:
- To review current knowledge on TB disease heterogeneity.
- To propose approaches for optimizing TB treatment duration based on patient stratification.
- To explore strategies for reducing TB treatment duration by integrating disease biology and pathology.
Main Methods:
- Review of existing literature on TB disease heterogeneity.
- Analysis of host and pathogen factors for patient stratification.
- Exploration of therapeutic strategies for distinct patient groups.
Main Results:
- Growing recognition of patient stratification as key to personalized TB treatment.
- Insights into bacterial vulnerabilities in easy-to-treat and hard-to-treat TB.
- Potential for reducing diagnostic uncertainties and optimizing treatment duration.
Conclusions:
- Patient stratification is crucial for tailoring TB treatment duration.
- Innovative strategies integrating disease biology can reduce treatment length.
- Rethinking therapeutic approaches is essential for efficient global TB control.
More Related Videos
09:34An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
09:57Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
Published on: December 14, 2016
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
COPD: Management Using Bronchodilators and Corticosteroids
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: